Phase 1 study of intraventricular 131I-omburtamab targeting B7H3 (CD276)-expressing CNS malignancies.

BACKGROUND: The prognosis for metastatic and recurrent tumors of the central nervous system (CNS) remains dismal, and the need for newer therapeutic targets and modalities is critical. The cell surface glycoprotein B7H3 is expressed on a range of solid tumors with a restricted expression on normal tissues. We hypothesized that compartmental radioimmunotherapy (cRIT) with the anti-B7H3 murine monoclonal antibody omburtamab injected intraventricularly could safely target CNS malignancies. PATIENTS AND METHODS: We conducted a phase I trial of intraventricular 131I-omburtamab using a standard 3 + 3 design. Eligibility criteria included adequate cerebrospinal fluid (CSF) flow, no major organ toxicity, and for patients > dose level 6, availability of autologous stem cells. Patients initially received 74 MBq radioiodinated omburtamab to evaluate dosimetry and biodistribution followed by therapeutic 131I-omburtamab dose-escalated from 370 to 2960 MBq. Patients were monitored clinically and biochemically for toxicity graded using CTCAEv 3.0. Dosimetry was evaluated using serial CSF and blood sampling, and serial PET or gamma-camera scans. Patients could receive a second cycle in the absence of grade 3/4 non-hematologic toxicity or progressive disease. RESULTS: Thirty-eight patients received 100 radioiodinated omburtamab injections. Diagnoses included metastatic neuroblastoma (n = 16) and other B7H3-expressing solid tumors (n = 22). Thirty-five patients received at least 1 cycle of treatment with both dosimetry and therapy doses. Acute toxicities included < grade 4 self-limited headache, vomiting or fever, and biochemical abnormalities. Grade 3/4 thrombocytopenia was the most common hematologic toxicity. Recommended phase 2 dose was 1850 MBq/injection. The median radiation dose to the CSF and blood by sampling was 1.01 and 0.04 mGy/MBq, respectively, showing a consistently high therapeutic advantage for CSF. Major organ exposure was well below maximum tolerated levels. In patients developing antidrug antibodies, blood clearance, and therefore therapeutic index, was significantly increased. In patients receiving cRIT for neuroblastoma, survival was markedly increased (median PFS 7.5 years) compared to historical data. CONCLUSIONS: cRIT with 131I-omburtamab is safe, has favorable dosimetry and may have a therapeutic benefit as adjuvant therapy for B7-H3-expressing leptomeningeal metastases. TRIAL REGISTRATION: clinicaltrials.gov NCT00089245, August 5, 2004.

Common and unusual craniofacial manifestations of metastatic neuroblastoma.

Although neuroblastoma is a common childhood malignancy, which frequently metastasizes, involvement of the facial bones and paranasal sinuses are uncommonly reported in the literature. However, over the last several years, we have encountered an increasing number of cases of metastatic neuroblastoma to the central nervous system and head and neck. This article will review the common and uncommon imaging manifestations of metastatic neuroblastoma, with emphasis on the orbits, maxillofacial bones, and paranasal sinuses.

Imaging of metastatic CNS neuroblastoma.

OBJECTIVE: Although neuroblastoma is a common childhood malignancy, which frequently metastasizes, involvement of the CNS is rarely reported in the literature. However, over the past several years, we have encountered an increasing number of cases of metastatic neuroblastoma to the CNS. This metastatic potential and changing metastatic pattern may, in part, be due to advances in medical treatment, leading to prolonged survival. This article will review the common and uncommon manifestations of metastatic neuroblastoma with an emphasis on the skull, dura, brain, ventricles, and leptomeninges. CONCLUSION: Neuroblastoma has diverse manifestations including masquerading as primary neurologic disease. This disease must be considered in a child with any unexplained neurologic disorder. Realizing that neuroblastoma may represent the cause of neurologic disease in a child will lead to earlier diagnosis.